

20 March 2024

BSF Enterprise PLC
("BSF" or the "Company")

Result of Annual General Meeting

BSF Enterprise (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues Ltd (3DBT) and corneal tissue replacement company Kerato Ltd, is pleased to announce that at the Company's Annual General Meeting held earlier today, all resolutions proposed were duly passed by shareholders by way of a poll, the results of which were as follows:

Resolution		Poll Results				
		For	Against	Withheld	Discretionary	Total
1	Shares	52,426,227	-	-	-	52,426,227
	%	100.00%	-	-	-	100%
2	Shares	52,421,227	5,000	-	-	52,426,227
	%	99.99%	0.01%	-	-	100%
3	Shares	52,421,227	5,000	-	-	52,426,227
	%	99.99%	0.01%	-	-	100%
4	Shares	52,426,227	-	-	-	52,426,227
	%	100.00%	-	-	-	100%
5	Shares	46,646,377	-	5,779,850	-	52,426,227
	%	88.98%	-	11.02%	-	100%
6	Shares	52,426,227	-	-	-	52,426,227
	%	100.00%	-	-	-	100%
7	Shares	52,402,826	23,401	-	-	52,426,227
	%	99.96%	0.04%	-	-	100%
8	Shares	52,421,227	-	5,000	-	52,426,227
	%	99.99%	-	0.01%	-	100%
9	Shares	52,397,826	23,401	5,000	-	52,426,227
	%	99.95%	0.04%	0.01%	-	100%

About BSF Enterprise PLC:

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cellbased tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors.

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas for testing to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality leather from its laboratory in Newcastle, transforming the leather industry towards an ethical and sustainable practice.

BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as through M&A. It aims to develop a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale.

For further enquiries, please visit www.bsfenterprise.com or contact:

BSF Enterprise PLC	Via SEC Newgate below
Geoff Baker - Executive Director	
Che Connon - CEO & Director	

Shard Capital (Broker)	
Damon Heath	0207 186 9000
Isabella Pierre	0207 186 9927

SEC Newgate (Financial Communications)	
Bob Huxford	020 3757 6882
Elisabeth Cowell	BSF@secnewgate.co.uk

*ISIN of the Ordinary Shares is GB00BHNBDQ51
SEDOL Code is BHNBDQ5.*